I wanted to know the current capacities that we are putting up, where are these peptide capacities? Are they inclined more towards SPPS or LPPS? And secondly, currently, based on whatever visibility talks we have with our partner, what is the longest chain of peptide that we are likely to manufacture on a meaningful size and scale? And if the length of chain increases, let's say, from 10 amino acid, they ask us to manufacture 20, does it require a meaningful regulatory approval, validation? And is there any lag time? Or is it going to be much shorter to turn around and supply them?
Questions across 1 call
Dhaval Khut
Jefferies